Waxman/Hatch Reform Should Clarify Rules, Not Change System - Merck

Reforms to the Waxman/Hatch patent extension program should focus on "clarification" of patent life, rather than "fundamental changes" to the generic drug approval and extension process, Merck Senior Director-Government Relations Ian Spatz told the National Institute for Health Care Management Sept. 25 in Washington, D.C.